Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR. (Q54301389)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

colorectal cancer

1 reference

based on heuristic

inferred from title

protein ubiquitination

1 reference

based on heuristic

inferred from title

author name string

Su Yao

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Ping Zheng

2

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Hua Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Li-Ming Song

4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Xiao-Fang Ying

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Cheng Xing

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Ying Li

7

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Zheng-Quan Xiao

8

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Xing-Ni Zhou

9

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Tong Shen

10

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Lin Chen

11

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Yu-Hong Liu

12

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Mao-De Lai

13

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Lin Mei

14

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Tian-Ming Gao

15

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Jian-Ming Li

16

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

publication date

20 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Journal of Pathology

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

236

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

65-77

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

ErbB receptors: from oncogenes to targeted cancer therapies

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Resistance to EGFR-targeted therapy: a family affair

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Erbin regulates NRG1 signaling and myelination

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

β2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Erbin suppresses the MAP kinase pathway

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Desmoglein-1/Erbin interaction suppresses ERK activation to support epidermal differentiation

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Erbin inhibits RAF activation by disrupting the sur-8-Ras-Raf complex

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Stathmin, a New Target of PRL-3 Identified by Proteomic Methods, Plays a Key Role in Progression and Metastasis of Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Identification of genes induced by BRCA1 in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Erbin-regulated sensitivity of MCF-7 breast cancer cells to TRAIL via ErbB2/AKT/NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Erbin inhibits transforming growth factor beta signaling through a novel Smad-interacting domain

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

ERBIN is a new SARA-interacting protein: competition between SARA and SMAD2 and SMAD3 for binding to ERBIN.

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Identification of three novel Smad binding proteins involved in cell polarity

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta.

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Erbin, a Negative Regulator in Diverse Signal Pathways

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

c-Myb Regulates Cell Cycle-Dependent Expression of Erbin: An Implication for a Novel Function of Erbin

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Role of Erbin in ErbB2-dependent breast tumor growth.

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

HER 2/neu expression and gene amplification in colon cancer

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Comparative analysis of the expression of ERBIN and Erb-B2 in normal human skin and cutaneous carcinomas

1 reference

https://api.crossref.org/works/10.1002/PATH.4502

21 January 2018

Identifiers

10.1002/PATH.4502

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25521828

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54301389&oldid=1240826440"